Portal de Periódicos da CAPES

Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors

2007; Elsevier BV; Volume: 35; Issue: 1 Linguagem: Inglês

10.1016/j.jsat.2007.08.004

1873-6483

Lynn E. Sullivan, Brent A. Moore, Marek C. Chawarski, Michael V. Pantalon, Declan T. Barry, Patrick G. O’Connor, Richard S. Schottenfeld, David A. Fiellin,

Substance Abuse Treatment and Outcomes

Methadone treatment reduces human immunodeficiency virus (HIV) risk, but the effects of primary-care-based buprenorphine/naloxone on HIV risk are unknown. The purpose of this study was to determine whether primary-care-based buprenorphine/naloxone was associated with decreased HIV risk behavior. We conducted a longitudinal analysis of 166 opioid-dependent persons (129 men and 37 women) receiving buprenorphine/naloxone treatment in a primary care clinic. We compared baseline and 12- and 24-week overall, drug-related, and sex-related HIV risk behaviors using the AIDS/HIV Risk Inventory (ARI). Buprenorphine/naloxone treatment was associated with significant reductions in overall and drug-related ARI scores from baseline to 12 and 24 weeks. Intravenous drug use in the past 3 months was endorsed by 37%, 12%, and 7% of patients at baseline and at 12 and 24 weeks, respectively (p < .001). Sex while you or your partner were “high” was endorsed by 64%, 13%, and 15% of patients at baseline and at 12 and 24 weeks, respectively (p < .001). Inconsistent condom use during sex with a steady partner was high at baseline and did not change over time. We conclude that primary-care-based buprenorphine/naloxone treatment is associated with decreased drug-related HIV risk, but additional efforts may be needed to address sex-related HIV risk when present (ClinicalTrials.gov number, NCT00023283).